Nosisbio offers the Connexa platform, which uses physics‑aware deep‑learning, high‑throughput chemistry, and single‑cell biology to design receptor‑targeted RNA delivery ligands and payloads for any cell type. By mapping a receptome of over 2,900 human cell‑specific receptors, the platform enables rapid, de‑risked development of subcutaneous, long‑acting RNA medicines with high specificity and low immunogenicity for chronic disease treatment.
Funding
Funding not disclosed
Founders
Product
Problem
Current RNA therapeutics are limited by the inability to deliver RNA molecules to specific cell types beyond the liver and muscle, requiring empirical, low‑throughput methods that hinder development of safe and effective gene‑silencing treatments for many chronic diseases.
Solution
Nosisbio’s Connexa platform combines physics‑aware deep‑learning models, high‑throughput chemistry, and single‑cell biology to design receptor‑targeted RNA delivery ligands and payloads at atom‑level precision. By mapping a “receptome” of over 2,900 cell‑specific human receptors, the platform can rationally select and co‑optimize delivery vehicles for any gene and any major tissue, including heart, lung, kidney, muscle, intestine, blood cells, and brain. Integrated in‑vivo validation pipelines enable functional delivery testing within 90 days, reducing the need for iterative lab work and de‑risking translational development. The result is a scalable, de‑risked path to subcutaneous, long‑acting RNA medicines that achieve high cell and gene specificity with low immunogenicity.
Target Audience
Primary customers are pharmaceutical and biotech companies developing RNA‑based therapeutics for chronic diseases that require cell‑type specific delivery, as well as research institutions seeking a high‑throughput platform for gene‑silencing drug discovery.
Features
- Receptome atlas covering the entire human proteome, identifying 2,900+ targetable cell‑specific receptors across major tissues
- Physics‑aware foundation AI model that designs ligand‑receptor interactions and RNA payloads at atom‑level resolution
- End‑to‑end workflow that incorporates in‑vivo validation of delivery ligands in less than 90 days
- Co‑design of delivery ligands and RNA payloads to optimize binding affinity, specificity, manufacturability, and interspecies translation
- Ability to generate subcutaneous RNA therapeutics with up to six‑month dosing intervals and non‑immunogenic profiles